Precision BioSciences (DTIL)
NASDAQ:DTIL
Want to see DTIL full AI Analyst Report?
DTIL Stock Chart & Stats
$7.88
-$0.10(-2.09%)
At close: 4:00 PM EST
$7.88
-$0.10(-2.09%)
Day’s Range― - ―
52-Week Range$3.53 - $8.82
Previous CloseN/A
Volume55.33K
Average Volume (3M)353.03K
Market Cap
$181.65M
Enterprise Value$9.06M
Total Cash (Recent Filing)$115.58M
Total Debt (Recent Filing)$28.81M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
May 13, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.05
Shares Outstanding25,803,200
10 Day Avg. Volume276,518
30 Day Avg. Volume353,026
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit0.28
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$36.33Price Target Upside361.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.94
Revenue Forecast (FY)$7.57M
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementInitiation of a first-in-human gene editor trial and supportive scientific presentations have increased analyst confidence in the program's clinical potential.
One-time Dosing PotentialTherapy is designed for one-time dosing and edits the dystrophin gene to produce a functional shortened protein, which could address a broader group of Duchenne patients compared with exon-specific approaches.
Regulatory StrategyManagement plans to engage the FDA after expanded cohort data to align on a potential pivotal trial and biologics license application, with a fast track designation potentially expediting review.
Bears Say
Competitive LandscapeA crowded Duchenne therapeutic area with exon-specific competitors could create competitive pressure on market adoption and valuation even if the program shows efficacy.
Limited Early DataEarly clinical readouts will come from very small patient cohorts, limiting certainty about safety and effectiveness and increasing result variability.
Viral Delivery Safety RiskUse of viral delivery carries inherent safety concerns, making the initial safety readout a critical determinant of whether the program can advance.
Precision BioSciences News
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.53 and its highest was $8.82 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $181.65M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is May 13, 2026 which is in 14 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Mar 12, 2026. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $1.585.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -0.66.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 25,803,200 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of $1.05 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went up 12.055%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precision BioSciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.33 (361.08% Upside)
$36.33 (361.08% Upside)
Blogger Sentiment
Bullish
DTIL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 787.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.97%
12-Months-Change
Fundamentals
Return on Equity
-96.96%
Trailing 12-Months
Asset Growth
13.22%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL Stock 12 Month Forecast
Average Price Target
$36.33
▲(361.08% Upside)
Technical Analysis
Ownership Overview
2.58% Insiders
4.29% Mutual Funds
0.17% Other Institutional Investors
89.28% Public Companies and
Individual Investors